1. Home
  2. OSRH vs ABP Comparison

OSRH vs ABP Comparison

Compare OSRH & ABP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OSR Holdings Inc.

OSRH

OSR Holdings Inc.

HOLD

Current Price

$0.60

Market Cap

14.2M

Sector

N/A

ML Signal

HOLD

ABP

Abpro Holdings Inc

HOLD

Current Price

$4.23

Market Cap

12.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OSRH
ABP
Founded
N/A
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.2M
12.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
OSRH
ABP
Price
$0.60
$4.23
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
N/A
AVG Volume (30 Days)
524.2K
18.2K
Earning Date
11-12-2025
02-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
50.00
52 Week Low
$0.45
$3.78
52 Week High
$12.54
$60.15

Technical Indicators

Market Signals
Indicator
OSRH
ABP
Relative Strength Index (RSI) 47.90 36.74
Support Level $0.55 $3.96
Resistance Level $0.60 $5.08
Average True Range (ATR) 0.06 0.41
MACD -0.00 -0.19
Stochastic Oscillator 34.85 17.33

Price Performance

Historical Comparison
OSRH
ABP

About OSRH OSR Holdings Inc.

OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea.

About ABP Abpro Holdings Inc

Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.

Share on Social Networks: